[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367214-105":59,"doc-detail-367214-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","exploring-zanidatamabs-efficacy-across-her2-positive-malignancies-a-narrative-review","Exploring Zanidatamab’s efficacy across HER2-positive Malignancies - a narrative review","","HER2-positive cancers are driven by amplification or overexpression of the HER2 gene, producing aggressive growth across breast, gastric, ovarian, and pancreatic tumor types. Detection approaches include immunohistochemistry, next-generation sequencing, and fluorescence in situ hybridization, with emerging tools such as biosensors and circulating tumor DNA to enhance diagnosis. Treatment evolution features anti-HER2 agents, including trastuzumab and zanidatamab, and the review synthesizes evidence on zanidatamab’s efficacy and safety in HER2-positive malignancies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/exploring-zanidatamabs-efficacy-across-her2-positive-malignancies-a-narrative-review/367214/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/exploring-zanidatamabs-efficacy-across-her2-positive-malignancies-a-narrative-review/367214.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is zanidatamab being studied for in HER2-positive malignancies?","Question",{"text":112,"@type":113},"The review focuses on zanidatamab’s efficacy and safety across cancers that are HER2-positive, including outcomes such as tumor response and progression-free survival.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were studies identified and selected for the narrative review?",{"text":117,"@type":113},"A comprehensive search was conducted in academic databases including PubMed, Cochrane Library, and clinicaltrials.gov. Studies were selected based on inclusion of relevant keywords and reporting zanidatamab treatment details.",{"name":119,"@type":110,"acceptedAnswer":120},"What does the review report about safety and tolerability?",{"text":121,"@type":113},"The safety profile has been studied, with common side effects including diarrhea and infusion reactions. In combination settings such as with Palbociclib for HER2-positive breast cancer, more severe adverse events were observed, and some patients discontinued treatment.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},367214,1790205588,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Kanwal etal. BMC Cancer (2025) 25:382 [https://doi.org/10.1186/s12885-025-13749-1](https://doi.org/10.1186/s12885-025-13749-1)  \nBMC Cancer  \n RESEARCH Open Access  \nExploring Zanidatamab’s efficacy  \nacross HER2-positive Malignancies: a narrative review  \nWarisha Kanwal1, Kaneez Narjis2, Sarah Musani3, Fnu Nancy4, Laiba Qureshi2, Muhammad Mudasir5, Rohma Naseem6, FnuTooba7, Juvairia Yousuf3, Kanza Farhan4, Hadiya Javed3 and  \nMohammed Mahmmoud Fadelallah Eljack8*  \nAbstract  \nBackground HER2-positive cancers involve amplification or overexpression of the HER2 gene, leading to aggressive tumor growth across several cancer types, including breast, gastric, ovarian, and pancreatic cancers. Detection methods such as immunohistochemistry, next-generation sequencing, and fluorescence in situ hybridization are used, with new advancements like biosensors and circulating tumor DNA offering improved diagnostic potential. Treatment strategies have evolved, including anti-HER2 drugs like trastuzumab and newer agents like zanidatamab, which show promise against HER2-positive malignancies.  \nMethods A comprehensive search of the following academic databases was performed including Pub  \nMed, Cochrane Library, and [clinicaltrials.gov. A detailed](clinicaltrials.gov. A detailed) search string was made. Studies were selected based on whether they contained the keywords and if they reported the details of treatment for zanidatamab. A total of 16 studies were selected. Abstracts were independently examined by one author and critically reviewed by another and if there were any conflicting viewpoints they were discussed until consensus was reached.  \nDiscussion Zanidatamab has shown promising clinical outcomes in several HER2-positive cancers, including biliary tract, breast, gastric, and lung cancers, with high disease control rates and progression-free survival. Although it is not yet FDA-approved, it has received priority review for HER2-positive biliary tract cancer, with an FDA decision expected in November 2024.  \nThe safety profile of zanidatamab has been well-studied. The most common side effects include diarrhea, infusion reactions, and other mild to moderate treatment-related adverse events. In combination with Palbociclib for HER2-positive breast cancer, more severe side effects were observed, resulting in some patients discontinuing treatment. However, no treatment-related deaths have been reported across trials.  \nWhile its anticancer efficacy and manageable safety profile are promising, long-term safety and efficacy data are still needed. Early clinical trials demonstrate strong efficacy, though some side effects, such as diarrhea and decreased ejection fraction, were noted. Future research should focus on understanding potential resistance mechanismsand establishing zanidatamab’s broader role in the treatment landscape of HER2-positive cancers.  \n*Correspondence:  \nMohammed Mahmmoud Fadelallah Eljack [m.mahmmoud96@gmail.com](m.mahmmoud96@gmail.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/.)[.](http","cbCaitdPV4K22B5q","https://ap.wps.com/l/cbCaitdPV4K22B5q","pdf",1143338,15,"English","# Background\n## HER2 biology and clinical relevance\n# Methods\n## Literature search and study selection\n# Discussion\n## Clinical outcomes across HER2-positive cancers\n## Safety profile and tolerability\n## Limitations and future directions","[{\"question\":\"What is zanidatamab being studied for in HER2-positive malignancies?\",\"answer\":\"The review focuses on zanidatamab’s efficacy and safety across cancers that are HER2-positive, including outcomes such as tumor response and progression-free survival.\"},{\"question\":\"How were studies identified and selected for the narrative review?\",\"answer\":\"A comprehensive search was conducted in academic databases including PubMed, Cochrane Library, and clinicaltrials.gov. Studies were selected based on inclusion of relevant keywords and reporting zanidatamab treatment details.\"},{\"question\":\"What does the review report about safety and tolerability?\",\"answer\":\"The safety profile has been studied, with common side effects including diarrhea and infusion reactions. In combination settings such as with Palbociclib for HER2-positive breast cancer, more severe adverse events were observed, and some patients discontinued treatment.\"}]","Exploring Zanidatamab’s efficacy across HER2-positive Malignancies - a narrative review | PDF",1790169733,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d84629de983fc51cc5810ada0eae70c3.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4340b3a41f25098e5e3ad8d2f2bcd37e.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2029d13294aa638c40afe5d07f319478.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/693a1352ebd262341bdb51eee562fbcd.webp",980,1301]